The FDA has approved benralizumab (Fasenra – AstraZeneca), a humanized monoclonal antibody selective for the interleukin-5 (IL-5) receptor, for add-on maintenance treatment of severe asthma in patients ≥12 years old with an eosinophilic phenotype. Benralizumab is the third anti-IL-5 antibody to be approved for treatment of severe eosinophilic asthma; mepolizumab (Nucala) and reslizumab (Cinqair), which target IL-5 itself, were approved earlier.1,2
Benralizumab (Fasenra) for Severe Eosinophilic Asthma. JAMA. 2018;319(14):1501–1502. doi:10.1001/jama.2018.3609
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: